Details of Drug-Drug Interaction
| Drug General Information (ID: DDI0WI9UEN) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Ranitidine (bismuth citrate) | Drug Info | Acalabrutinib | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiulcer Agents | Antineoplastics/Bruton Tyrosine Kinase Inhibitor | |||||||
| Structure | |||||||||
| Mechanism of Ranitidine (bismuth citrate)-Acalabrutinib Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Altered gastric pH Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Ranitidine (bismuth citrate) | Acalabrutinib | |||||||
| Mechanism | Gastric alkalinizer | Gastric pH sensitive | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Gastric pH | ||||||||
| Factor Description | The normal pH range of gastric acid is between 1.5 and 3.5 and is highly acidic, consisting mainly of hydrochloric acid. Changes in the pH of the stomach can alter the absorption of drugs. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Concomitant use of acalabrutinib with proton pump inhibitors should generally be avoided. If acid suppression therapy is required, H2-receptor antagonists or antacids should be considered. The manufacturer recommends taking acalabrutinib 2 hours before H2-receptor antagonists and separating the dosing of antacids by at least 2 hours. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||||||||||||||||